Research Papers:

Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer

Xijuan Wang, Peng An, Jiling Zeng, Xiaoyan Liu, Bo Wang, Xuexian Fang, Fudi Wang, Guoping Ren and Junxia Min _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:17862-17872. https://doi.org/10.18632/oncotarget.14977

Metrics: PDF 3369 views  |   HTML 3600 views  |   ?  


Xijuan Wang1,*, Peng An1,*, Jiling Zeng1, Xiaoyan Liu1, Bo Wang1, Xuexian Fang1, Fudi Wang1,2, Guoping Ren1, Junxia Min1

1The First Affiliated Hospital, Institute of Translational Medicine, School of Public Health, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Medicine, Zhejiang University, Hangzhou 310058, China

2Department of Nutrition, Precision Nutrition Innovation Center, School of Public Health, Zhengzhou University, Zhengzhou 450001, China

*These authors contributed equally to this work

Correspondence to:

Junxia Min, email: [email protected]

Guoping Ren, email: [email protected]

Fudi Wang, email: [email protected], [email protected]

Keywords: prostate cancer, ferritin, PSA

Received: September 20, 2016     Accepted: January 24, 2017     Published: February 01, 2017


Ferritin is highly expressed in many cancer types. Although a few studies have reported an association between high serum ferritin levels and an increased risk of prostate cancer, the results are inconsistent. Therefore, we performed a large case-control study consisting of 2002 prostate cancer patients and 951 control patients with benign prostatic hyperplasia (BPH). We found that high ferritin levels were positively associated with increased serum prostate-specific antigen (PSA) levels and prostate cancer risk; each 100 ng/ml increase in serum ferritin increased the odds ratio (OR) by 1.20 (95% CI: 1.13−1.36). In the prostate cancer group, increased serum ferritin levels were significantly correlated with higher Gleason scores (p < 0.001). Notably, serum PSA values had even higher predictive accuracy among prostate cancer patients with serum ferritin levels > 400 ng/ml (Gleason score + total PSA correlation: r = 0.38; Gleason score + free PSA correlation: r = 0.49). Moreover, using immunohistochemistry, we found that prostate tissue ferritin levels were significantly higher (p < 0.001) in prostate cancer patients (n = 129) compared to BPH controls (n = 31). Prostate tissue ferritin levels were also highly correlated with serum ferritin when patients were classified by cancer severity (r = 0.81). Importantly, we found no correlation between serum ferritin levels and the inflammation marker C-reactive protein (CRP) in prostate cancer patients. In conclusion, serum ferritin is significantly associated with prostate cancer and may serve as a non-invasive biomarker to complement the PSA test in the diagnosis and prognostic evaluation of prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14977